From carcinogenesis to clinical interventions for cancer prevention

Authors
Citation
P. Greenwald, From carcinogenesis to clinical interventions for cancer prevention, TOXICOLOGY, 166(1-2), 2001, pp. 37-45
Citations number
46
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Toxicology
Journal title
TOXICOLOGY
ISSN journal
0300-483X → ACNP
Volume
166
Issue
1-2
Year of publication
2001
Pages
37 - 45
Database
ISI
SICI code
0300-483X(20010914)166:1-2<37:FCTCIF>2.0.ZU;2-B
Abstract
During the last three decades, the scientific community has made immense pr ogress in acquiring the knowledge needed to prevent cancer. Pioneering rese arch helped to identify potential causes of cancer, particularly environmen tal factors such as diet, and provided insight regarding their mechanisms-o f-action. Concurrently, promising inhibitors of cancer that appeared able t o either arrest or reverse cancer development by interfering with one or mo re steps in the process of carcinogenesis were identified and systematicall y evaluated for their potential as chemopreventive agents. Numerous agents determined to be safe and effective in preclinical trials have been and con tinue to be tested in Phase I, II, and III clinical interventions for cance rs at various sites, including breast, colon, prostate, esophagus, mouth, l ung, cervix, endometrium, ovary, liver, bladder, and skin. The development of valid intermediate biomarkers that can serve as surrogate endpoints For clinical disease is urgently needed to accelerate advances in clinical tria ls for cancer prevention.